HRP20090009T3 - N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
HRP20090009T3
HRP20090009T3 HR20090009T HRP20090009T HRP20090009T3 HR P20090009 T3 HRP20090009 T3 HR P20090009T3 HR 20090009 T HR20090009 T HR 20090009T HR P20090009 T HRP20090009 T HR P20090009T HR P20090009 T3 HRP20090009 T3 HR P20090009T3
Authority
HR
Croatia
Prior art keywords
alkyl
aryl
group
heteroaryl
substituted
Prior art date
Application number
HR20090009T
Other languages
English (en)
Croatian (hr)
Inventor
R. V. Finlay Maurice
Waterson David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20090009T3 publication Critical patent/HRP20090009T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20090009T 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors HRP20090009T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20090009T3 true HRP20090009T3 (en) 2009-02-28

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090009T HRP20090009T3 (en) 2003-06-27 2004-06-23 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (33)

Country Link
US (1) US7485644B2 (enExample)
EP (1) EP1644340B1 (enExample)
JP (1) JP4701167B2 (enExample)
KR (1) KR20060026440A (enExample)
CN (2) CN1812974B (enExample)
AR (1) AR044931A1 (enExample)
AT (1) ATE414063T1 (enExample)
AU (1) AU2004251104B2 (enExample)
BR (1) BRPI0411929A (enExample)
CA (1) CA2529468A1 (enExample)
CO (1) CO5650254A2 (enExample)
CY (1) CY1108757T1 (enExample)
DE (1) DE602004017733D1 (enExample)
DK (1) DK1644340T3 (enExample)
ES (1) ES2315675T3 (enExample)
HR (1) HRP20090009T3 (enExample)
IL (1) IL172615A0 (enExample)
IS (1) IS8257A (enExample)
MX (1) MXPA05013460A (enExample)
MY (1) MY138680A (enExample)
NO (1) NO20060444L (enExample)
NZ (1) NZ544208A (enExample)
PL (1) PL1644340T3 (enExample)
PT (1) PT1644340E (enExample)
RU (1) RU2351595C2 (enExample)
SA (1) SA04250224B1 (enExample)
SE (1) SE0301922D0 (enExample)
SI (1) SI1644340T1 (enExample)
TW (1) TW200524898A (enExample)
UA (1) UA81491C2 (enExample)
UY (1) UY28387A1 (enExample)
WO (1) WO2005000822A1 (enExample)
ZA (1) ZA200510458B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
HUE030114T2 (en) * 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivatives and pharmaceutical compositions containing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100266A (en) * 1998-01-30 2000-08-08 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CN1159295C (zh) * 1999-06-04 2004-07-28 阿斯特拉曾尼卡有限公司 金属蛋白酶抑制剂
CA2396965C (en) 2000-02-21 2010-03-16 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
BR0309671A (pt) * 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
CA2528317A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
AU2004251104A1 (en) 2005-01-06
UA81491C2 (en) 2008-01-10
MXPA05013460A (es) 2006-03-09
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
CN1812974B (zh) 2011-06-29
CN1812974A (zh) 2006-08-02
DE602004017733D1 (de) 2008-12-24
CA2529468A1 (en) 2005-01-06
AR044931A1 (es) 2005-10-12
KR20060026440A (ko) 2006-03-23
PT1644340E (pt) 2009-01-02
US7485644B2 (en) 2009-02-03
IL172615A0 (en) 2006-04-10
UY28387A1 (es) 2005-01-31
CO5650254A2 (es) 2006-06-30
AU2004251104B2 (en) 2008-05-08
SE0301922D0 (sv) 2003-06-27
JP4701167B2 (ja) 2011-06-15
JP2007516164A (ja) 2007-06-21
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
SI1644340T1 (sl) 2009-02-28
RU2351595C2 (ru) 2009-04-10
HK1086835A1 (en) 2006-09-29
IS8257A (is) 2006-01-23
WO2005000822A1 (en) 2005-01-06
ES2315675T3 (es) 2009-04-01
EP1644340B1 (en) 2008-11-12
TW200524898A (en) 2005-08-01
PL1644340T3 (pl) 2009-04-30
BRPI0411929A (pt) 2006-08-15
EP1644340A1 (en) 2006-04-12
CY1108757T1 (el) 2014-04-09
MY138680A (en) 2009-07-31
ATE414063T1 (de) 2008-11-15
CN102229589A (zh) 2011-11-02
RU2005141058A (ru) 2006-07-27
US20070197542A1 (en) 2007-08-23
DK1644340T3 (da) 2009-02-02

Similar Documents

Publication Publication Date Title
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
HRP20080120T3 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
DK0402644T3 (da) N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
BRPI0211844B8 (pt) composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
CO5011090A1 (es) Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
YU39698A (sh) Hinoksalindioni
FI832648A0 (fi) Dihydropyridiner som antiischemiska och antihypertensiva laekemedel
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
HRP20080490T3 (en) 3-fluoro-piperidines as nmda/nr2b antagonists
BR112022002674A2 (pt) Derivado de 2-aminoquinazolinona
HRP20090009T3 (en) N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
HRP20090101T3 (en) N-(1h-indolyl)-h-indole-2-carboxamide derivatives, their preparation and their therapeutic use
DK0962457T3 (da) Piperidoner som tachykininantagonister
GB1455987A (en) Pyrido 1,2-a- pyrimidinone derivatives useful as pharmaceuticals
BR112022021920A2 (pt) Síntese de compostos heterocíclicos
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
NO20062258L (no) Nye metoder